Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer

BACKGROUND: Cabazitaxel is approved for treatment of castration-resistant metastatic prostate cancer. The current dosing strategy of cabazitaxel is based on body surface area (BSA). Body surface area is known as a poor predictor for total systemic exposure to drugs, since it does not take into accou...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Janssen, A, Verkleij, C P M, van der Vlist, A, Mathijssen, R H J, Bloemendal, H J, ter Heine, R
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482735/
https://ncbi.nlm.nih.gov/pubmed/28399110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.91
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars